Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: A retrospective cohort study

Clinical Microbiology and Infection

Volumn 16, Issue 6, 2010, Pages 722-728

  Rubio Terres C ^a   Garau, J ^b   Grau, S ^c   Martinez Martinez, L ^d  

^a Health Economics and Outcomes Research IMS Health   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Gram positive; MRSA; Pharmaco economics; Resistance; Spain

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 77953953266     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02902.x     Document Type: Article

References (20)

1. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42(suppl):S82-S89.
2. Cuevas O, Cercenado E, Vindel A. Evolution of the antimicrobial resistance of Staphylococcusspp. in Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004, 48:4240-4245.
3. Hanberger H, Burman LG, Cars O. Low antibiotic resistance rates in Staphylococcus aureus, Escherichia coli and Klebsiella spp. but not in Enterobacter spp. and Pseudomonas aeruginosa: a prospective observational study in 14 Swedish ICUs over a 5-year period. Acta Anaesthesiol Scand 2007, 51:937-941.
4. Hanssen AM, Fossum A, Mikalsen J, Halvorsen DS, Bukholm G, Sollid JU. Dissemination of community-acquired methicillin-resistant Staphylococcus aureus clones in northern Norway: sequence types 8 and 80 predominate. J Clin Microbiol 2005, 43:2118-2124.
5. Larsen AR, Böcher S, Stegger M, Goering R, Pallesen LV, Skov R. Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004. J Clin Microbiol 2008, 46:62-68.
6. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999, 282:1745-1751.
7. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999, 20:408-411.
8. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998, 158:182-189.
9. Cisneros-Herreros JM, Cobo-Reinoso J, Pujol-Rojo M, Rodriguez-Bano J, Salavert-Lleti M. Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. Enferm Infecc Microbiol Clin 2007, 25:111-130.
10. Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Gomez M, Lopez F. Antimicrobial resistance surveillance: VIRA study 2006. Enferm Infecc Microbiol Clin 2006, 24:617-628.
11. Kelsey JL, Thompson WD, Evans A. Methods in observational epidemiology 1986, New York, Oxford University Press
12. Performance standards for antimicrobial susceptibility testing 2005, Fifteenth informational supplement ASM-SC, Wayne, PA, CLSI
13. Morís de la Tassa J, Fernández P, Antuña A. Estudio de los costes asociados a la bacteriemia relacionada con el catéter. Rev Clin Esp 1998, 198:641-646.
14. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
15. Reed SD, Friedman JY, Engemann JJ. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005, 26:175-183.
16. Paladino JA. Economic justification of antimicrobial management programs: implications of antimicrobial resistance. Am J Health Syst Pharm 2000, 57(suppl):S10-S12.
17. Resch A, Wilke M, Fink C. The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ 2009, 10:287-297.
18. Shorr AF, Micek ST, Kollef MH. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Crit Care Med 2008, 36:2335-2340.
19. Nulens E, Broex E, Ament A. Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital. J Hosp Infect 2008, 68:301-307.
20. Vriens M, Blok H, Fluit A. Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002, 21:782-786.